Scholarlink

Purpose <p>To evaluate the efficacy and safety of renal artery embolization (RAE) in hypervascular renal tumors using Tantalum-Loaded Obsidio™ Conformable Embolic (Ta-OCE).</p> Methods <p>A single-center institutional review board (IRB) approved retrospective analysis of consecutive patients with benign and malignant hypervascular renal tumors treated with Ta-OCE between May 2023 and June 2024 was performed. Specific clinical data on tumor size reduction, renal function preservation, bleeding, and complications were collected. Follow-up imaging was conducted using MRI or CT scans. Adverse events were evaluated according to the Common Toxicity Criteria for Adverse Events (v.5). Student’s t-test was used to compare continuous variables.</p> Results <p>Overall, <i>N</i> = 10 patients (mean age 64.1 + 14.9 (SD) years, 46% female) were included; 5 patients with renal cell carcinoma (RCC) and 5 patients with angiomyolipoma (AML). Technical success was achieved in all 10 patients. There was a significant reduction in tumor diameter of 1.03&#xa0;cm following embolization (<i>p</i> = 0.0009). There was no significant change in renal function post-RAE at 1&#xa0;month, GFR pre-(72.8 ± 23.5&#xa0;mL/min/1.73 m<sup>2</sup>, GFR post 63 ± 24.7&#xa0;mL/min/1.73 m<sup>2</sup>, with a mean change in GFR (%) of − 13.5 ± 11.2%. (<i>p</i> = 0.116). Additionally, no significant bleeding requiring further intervention was experienced. One patient experienced a Grade 1 adverse effect due to an underlying heart condition.</p> Conclusion <p>Embolization of hypervascular renal tumors with Ta-OCE appears to be safe and effective. Prospective, ideally multicenter studies are needed to further clarify the ideal scenarios for the use of Ta-OCE in hypervascular renal tumors.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Technical and Clinical Outcomes of Embolization of Hypervascular Renal Tumors Using Tantalum-Loaded Obsidio Conformable Embolic (Ta-OCE): a single-center experience

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月17日

查看全文
  • Sandra Gad,
  • Michael Mohnasky,
  • Zachary Schrank,
  • Bryan Harris,
  • Priya Mody,
  • Alexander Villalobos,
  • Andrew Caddell,
  • Arianna Dezfulian,
  • Nima Kokabi

摘要

Purpose

To evaluate the efficacy and safety of renal artery embolization (RAE) in hypervascular renal tumors using Tantalum-Loaded Obsidio™ Conformable Embolic (Ta-OCE).

Methods

A single-center institutional review board (IRB) approved retrospective analysis of consecutive patients with benign and malignant hypervascular renal tumors treated with Ta-OCE between May 2023 and June 2024 was performed. Specific clinical data on tumor size reduction, renal function preservation, bleeding, and complications were collected. Follow-up imaging was conducted using MRI or CT scans. Adverse events were evaluated according to the Common Toxicity Criteria for Adverse Events (v.5). Student’s t-test was used to compare continuous variables.

Results

Overall, N = 10 patients (mean age 64.1 + 14.9 (SD) years, 46% female) were included; 5 patients with renal cell carcinoma (RCC) and 5 patients with angiomyolipoma (AML). Technical success was achieved in all 10 patients. There was a significant reduction in tumor diameter of 1.03 cm following embolization (p = 0.0009). There was no significant change in renal function post-RAE at 1 month, GFR pre-(72.8 ± 23.5 mL/min/1.73 m2, GFR post 63 ± 24.7 mL/min/1.73 m2, with a mean change in GFR (%) of − 13.5 ± 11.2%. (p = 0.116). Additionally, no significant bleeding requiring further intervention was experienced. One patient experienced a Grade 1 adverse effect due to an underlying heart condition.

Conclusion

Embolization of hypervascular renal tumors with Ta-OCE appears to be safe and effective. Prospective, ideally multicenter studies are needed to further clarify the ideal scenarios for the use of Ta-OCE in hypervascular renal tumors.

Graphical Abstract